BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...digital health company’s CorVista system collects and applies machine learning to a patient’s cardiac and hemodynamic...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...human diseases in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

Aerovate emerged from RA Capital’s incubator last week with a $72.6 million series A round to support clinical testing of an inhaled dry powder formulation of imatinib for PAH that’s designed to avoid the systemic...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...the therapies take different approaches. Atrasentan, an antagonist of endothelin receptor A, affects the kidney’s hemodynamic...
BioCentury | Feb 21, 2019
Financial News

Shukun raises RMB200M series B round for AI diagnostics

...software platform for cardiovascular and cerebrovascular diseases uses medical imaging analysis for diagnosis, 3-D reconstruction, hemodynamic...
BioCentury | Oct 20, 2017
Company News

HemoShear, Takeda in liver disease deal

...in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Oct 17, 2017
Company News

HemoShear, Takeda in liver disease deal

...in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Jul 21, 2017
Strategy

Accessing miracles

...the side effect, successfully preventing any CRS-related deaths. The algorithm starts with oxygen to provide hemodynamic...
...second-line treatment includes the IL-6 inhibitor Actemra tocilizumab from Roche , as well as additional hemodynamic...
BioCentury | Jan 27, 2017
Clinical News

Opsumit: Ph III MAESTRO data

...a subgroup of 39 patients with Eisenmenger syndrome in which the effects of Opsumit on hemodynamic...
BioCentury | Jan 18, 2017
Clinical News

PLX-PAD cells: Completed Ph II enrollment

Pluristem completed enrollment of 172 patients in a double-blind, placebo-controlled, international Phase II trial evaluating 150 and 300 million PLX-PAD cells administered via 2 intramuscular injections 12 weeks apart. Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI),...
Items per page:
1 - 10 of 182
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...digital health company’s CorVista system collects and applies machine learning to a patient’s cardiac and hemodynamic...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...human diseases in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Aug 13, 2020
Emerging Company Profile

RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH

Aerovate emerged from RA Capital’s incubator last week with a $72.6 million series A round to support clinical testing of an inhaled dry powder formulation of imatinib for PAH that’s designed to avoid the systemic...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...the therapies take different approaches. Atrasentan, an antagonist of endothelin receptor A, affects the kidney’s hemodynamic...
BioCentury | Feb 21, 2019
Financial News

Shukun raises RMB200M series B round for AI diagnostics

...software platform for cardiovascular and cerebrovascular diseases uses medical imaging analysis for diagnosis, 3-D reconstruction, hemodynamic...
BioCentury | Oct 20, 2017
Company News

HemoShear, Takeda in liver disease deal

...in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Oct 17, 2017
Company News

HemoShear, Takeda in liver disease deal

...in vitro by subjecting 3D cultures of primary patient cells to physiological phenomena such as hemodynamic...
BioCentury | Jul 21, 2017
Strategy

Accessing miracles

...the side effect, successfully preventing any CRS-related deaths. The algorithm starts with oxygen to provide hemodynamic...
...second-line treatment includes the IL-6 inhibitor Actemra tocilizumab from Roche , as well as additional hemodynamic...
BioCentury | Jan 27, 2017
Clinical News

Opsumit: Ph III MAESTRO data

...a subgroup of 39 patients with Eisenmenger syndrome in which the effects of Opsumit on hemodynamic...
BioCentury | Jan 18, 2017
Clinical News

PLX-PAD cells: Completed Ph II enrollment

Pluristem completed enrollment of 172 patients in a double-blind, placebo-controlled, international Phase II trial evaluating 150 and 300 million PLX-PAD cells administered via 2 intramuscular injections 12 weeks apart. Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI),...
Items per page:
1 - 10 of 182